[Correspondence] PD-1 inhibition in sarcoma still needs investigation – Authors’ reply

We appreciate the opportunity to respond to Maud Toulmonde and Antoine Italiano's letter. SARC028 was a phase 2 study evaluating the safety and activity of PD-1 inhibition in advanced bone and soft tissue sarcomas and emphasised collection of biospecimens to explore immune-related biomarkers.1 We used objective response as our primary endpoint because this was a signal-finding study. We limited the soft tissue sarcoma cohort to ten patients in each of four common soft tissue sarcoma subtypes to obtain pilot data.

http://ift.tt/2zNhJRh